The Santa Monica meeting has become a cornerstone of the regional IASLC meetings, and a forum for investigators to learn about the latest therapies and for companies to interact with investigators to plan the next generation of clinical trials in lung cancer.
With the start of a new year, we see new opportunities on the horizon with lung cancer treatments and we must work to maximize their impact and potential. With the approval of alectinib and osimertinib, we continue to see the rapid rise in the options available to our patients, and your IASLC continues its commitment to educate the oncology community and patients on these new developments.
November is known in the U.S. for the holiday of “Thanksgiving,” celebrating the good fortunes of the previous year. The past year has seen continuing significant advances in the management of lung cancer, with more to come.
The pace of progress in lung cancer is truly amazing and gratifying. In the last few weeks one immunotherapy drug was approved for lung cancer in the USA and another received an expanded indication. We have exciting data on the activity of these agents in small cell lung cancer and mesothelioma presented at the WCLC, and another new drug in small cell presented first there and advancing in clinical trials. New genetic targets are showing their impact on targeted therapies.